Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Marinus Pharmaceuticals I...

    NASDAQ: MRNS · Real-Time Price · USD
    0.55
    0.00 (0.00%)
    At close: Feb 10, 2025, 3:59 PM
    0.00%
    Bid 0.55
    Market Cap 30.37M
    Revenue (ttm) 30.26M
    Net Income (ttm) -149.24M
    EPS (ttm) -2.47
    PE Ratio (ttm) -0.22267206477732793
    Forward PE -2.62
    Analyst Hold
    Ask 0.55
    Volume 1,100,953
    Avg. Volume (20D) 1,810,773
    Open 0.55
    Previous Close 0.55
    Day's Range 0.55 - 0.55
    52-Week Range 0.22 - 10.50
    Beta 1.26

    About MRNS

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol MRNS
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for MRNS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Marinus Pharmaceuticals Inc. is scheduled to release its earnings on May 2, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    4 months ago
    Marinus Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription
    6 months ago
    Marinus Pharmaceuticals shares are trading lower after the company announced its Phase 3 TrustTSC trial of Oral Ganaxolone did not meet its primary endpoint.
    news image

    4 months ago · zacks.com

    Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know

    Marinus Pharmaceuticals (MRNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    news image

    4 months ago · businesswire.com

    MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS

    NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Marinus Pharmace...

    news image

    4 months ago · businesswire.com

    Shareholder Alert: Ademi LLP Investigates Whether Marinus Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders

    MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Marinus (Nasdaq: MRNS) for possible breaches of fiduciary duty and other violations of law in its transaction with the Immedica. Click here to le...

    news image

    4 months ago · businesswire.com

    MRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to Shareholders

    NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) to Immedica Pharma AB for $0.55 per share is...

    news image

    4 months ago · businesswire.com

    Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.

    STOCKHOLM & RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceuti...

    Add to Watchlist